Angela Zhao

Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US

A. Guo, T. Lodise, M. Bochan, 2023, Advances in therapy.

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA

A. Guo, T. Lodise, M. Bochan, 2023, Advances in Therapy.

Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia

L. Chuang, Zhihao Yang, Xueyun Zeng, 2023, Health and Quality of Life Outcomes.

Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis

Angela Zhao, Walter Toro, Min Yang, 2023, Advances in therapy.